RxDoctor Payments Data

Abdallah Dawod, MD

Family Medicine · Altus, OKNPI 1174519771

Payments from drug & device makers

$2,797in general payments, 2019–2025

Across 163 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$763
  • AstraZeneca$395
  • Boehringer Ingelheim$347
  • Pfizer$208
  • Medtronic$173
  • GSK$157
  • plus $754 from 20 others

What the payments were for

  • Food & beverage$2,786100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,797 in reported general payments places this provider in the 75th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$254,990
Medicare patients
505
Services billed
6,682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide260$304,395
EliquisApixaban207$118,697
OzempicSemaglutide93$109,969
JanuviaSitagliptin Phosphate97$78,628
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$61,755
TrulicityDulaglutide58$54,995
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog45$49,617
FarxigaDapagliflozin Propanediol45$48,795
JardianceEmpagliflozin54$43,786
Tresiba Flextouch U-200Insulin Degludec22$31,994
TradjentaLinagliptin29$29,685
Janumet XrSitagliptin Phos/Metformin Hcl40$25,842
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog38$24,413
JanumetSitagliptin Phos/Metformin Hcl35$19,035
Soliqua 100-33Insulin Glargine/Lixisenatide14$17,992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$763$359,390318 claims
MerckJanuvia, Janumet Xr, Janumet, Belsomra$17$131,631191 claims
PfizerEliquis$208$118,697207 claims
Novo NordiskOzempic$17$109,96993 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$347$84,19294 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$157$70,772103 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$395$68,79588 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$60$22,88242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Altus

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →